PathoGenesis is Outward Bound
Executive Summary
PathoGenesis has begun life serving the niche market of cystic fibrosis. But the firm says this focused business model is just the launch point for expansion into other, larger chronic infectious respiratory markets.
You may also be interested in...
Ocularis Pharma Inc.
Ocularis has found a simple solution-a drug delivered in the form of eyedrops-for the problem of impaired night vision. Poor night vision is a generally unrecognized and largely unstudied phenomenon, but it affects every fourth person, the company believes. Because it's working with a new formulation of an already-approved drug that's available in an injectable formulation for a different indication, it's been able to move quickly into clinical trials.
New EU Approvals
The Pink Sheet's list of EU centralized approvals of new active substances has been updated to add two new products, including Ryzneuta, Evive Biotechnology's treatment for chemotherapy-induced neutropenia.
Pair Of Deaths Linked To Recalled Vyaire Medical Respiratory Devices
The US FDA has labelled a recall of more than 6 million Airlife respiratory support devices class I. The recall covers devices manufactured in 2017 or earlier that can fail to provide adequate ventilation.